Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Meet Our Best Sellers Science-backed formulas our customers come back to again and again
Main GLP1 and Related Brands Leading GLP-1 medications in 2025 include semaglutide (marketed as Ozempic for diabetes and Wegovy for weight loss), liraglutide (Victoza for diabetes, Saxenda for weight loss), tirzepatide (Mounjaro for diabetes, Zepbound for weight loss), dulaglutide (Trulicity for diabetes) and oral semaglutide (Rybelsus)
So far, the trials seem to show: high reduction in weight, hovering around 28% for those on a 12-milligram dose self-reported improvements in cardiometabolic risk factors like high blood pressure, insulin, and fasting glucose promising results for type 2 diabetes and fatty liver disease a reduction in pain from knee osteoarthritis Retatrutide may be valuable for those who have had limited success with other weight loss drugs, have a higher BMI, or are at significant metabolic risk
People stop taking Rybelsus because the morning routine feels too demanding, quit injectables because weekly shots become burdensome, or stop Foundayo when nausea persists and no one helps adjust dosing or meal timing
The study utilized Cox proportional hazards and Kaplan-Meier survival analyses to assess the risk differences, reporting hazard ratios (HRs), and 95% confidence intervals (CIs)
Dosage Effect Dose-response findings belong to the specific clinical trial
